An Analysis of Patients Undergoing Surgical Removal of the Essure Device: A Retrospective Case Series

Yonghee K. Cho, Samantha Nguyen, Gerald Harkins, Timothy Deimling, Andrea Benton

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this research was to describe and investigate characteristics of patients who underwent surgical removal of the Essure® device (Bayer, Whippany, NJ). This device was the first transcervical micro insert device for permanent sterilization. Materials and Methods: A retrospective chart review was conducted at an academic hospital on patients undergoing surgical removal of the Essure device from 2014 to 2017. Results: A total of 69 patients underwent Essure removal-25 via laparoscopic hysterectomy, 38 via salpingectomy with cornual resection, and 6 via salpingectomy without cornual resection. The mean age of the subjects was 36.4 years (standard deviation [SD] = 7.2). The mean body mass index was 31.7 (SD = 7.3). The most-commonly reported past medical histories were anxiety (19/69) and depression (16/69). Thirty-eight patients had histories of prior surgeries, with cesarean section being reported most commonly (22/38). The most-frequently cited Essure-attributed symptoms were pelvic pain (63/69), bleeding (34/69), and bloating (15/69). When removal was requested, 58/69 patients had had the device in for >1 year and 44/69 patients reported onset of symptoms at time of placement. During the removal surgery, 59/69 patients had additional pelvic intraoperative findings; specifically, 43/69 had endometriosis, 24/69 had adhesions, 22/69 had adenomyosis, 8/69 had fibroids; and 7/69 had misplaced coils. The majority of fallopian tubes were normal/no pathologic alterations (35/69), with smaller subsets of patients having paratubal cysts (26/69) and fibrosis (5/69). Conclusions: Patients seeking removal of the Essure device might have coexisting pelvic pathology. Providers should be prepared to address any intraoperative pathology found.

Original languageEnglish (US)
Pages (from-to)285-288
Number of pages4
JournalJournal of Gynecologic Surgery
Volume35
Issue number5
DOIs
StatePublished - Oct 2019

Fingerprint

Device Removal
Salpingectomy
Equipment and Supplies
Parovarian Cyst
Pathology
Adenomyosis
Pelvic Pain
Fallopian Tubes
Leiomyoma
Endometriosis
Hysterectomy
Cesarean Section
Body Mass Index
Fibrosis
Anxiety
Depression
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Surgery
  • Obstetrics and Gynecology

Cite this

@article{5b1813665762445a898565104de4f564,
title = "An Analysis of Patients Undergoing Surgical Removal of the Essure Device: A Retrospective Case Series",
abstract = "Objective: The aim of this research was to describe and investigate characteristics of patients who underwent surgical removal of the Essure{\circledR} device (Bayer, Whippany, NJ). This device was the first transcervical micro insert device for permanent sterilization. Materials and Methods: A retrospective chart review was conducted at an academic hospital on patients undergoing surgical removal of the Essure device from 2014 to 2017. Results: A total of 69 patients underwent Essure removal-25 via laparoscopic hysterectomy, 38 via salpingectomy with cornual resection, and 6 via salpingectomy without cornual resection. The mean age of the subjects was 36.4 years (standard deviation [SD] = 7.2). The mean body mass index was 31.7 (SD = 7.3). The most-commonly reported past medical histories were anxiety (19/69) and depression (16/69). Thirty-eight patients had histories of prior surgeries, with cesarean section being reported most commonly (22/38). The most-frequently cited Essure-attributed symptoms were pelvic pain (63/69), bleeding (34/69), and bloating (15/69). When removal was requested, 58/69 patients had had the device in for >1 year and 44/69 patients reported onset of symptoms at time of placement. During the removal surgery, 59/69 patients had additional pelvic intraoperative findings; specifically, 43/69 had endometriosis, 24/69 had adhesions, 22/69 had adenomyosis, 8/69 had fibroids; and 7/69 had misplaced coils. The majority of fallopian tubes were normal/no pathologic alterations (35/69), with smaller subsets of patients having paratubal cysts (26/69) and fibrosis (5/69). Conclusions: Patients seeking removal of the Essure device might have coexisting pelvic pathology. Providers should be prepared to address any intraoperative pathology found.",
author = "Cho, {Yonghee K.} and Samantha Nguyen and Gerald Harkins and Timothy Deimling and Andrea Benton",
year = "2019",
month = "10",
doi = "10.1089/gyn.2018.0111",
language = "English (US)",
volume = "35",
pages = "285--288",
journal = "Journal of Gynecologic Surgery",
issn = "1042-4067",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

An Analysis of Patients Undergoing Surgical Removal of the Essure Device : A Retrospective Case Series. / Cho, Yonghee K.; Nguyen, Samantha; Harkins, Gerald; Deimling, Timothy; Benton, Andrea.

In: Journal of Gynecologic Surgery, Vol. 35, No. 5, 10.2019, p. 285-288.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An Analysis of Patients Undergoing Surgical Removal of the Essure Device

T2 - A Retrospective Case Series

AU - Cho, Yonghee K.

AU - Nguyen, Samantha

AU - Harkins, Gerald

AU - Deimling, Timothy

AU - Benton, Andrea

PY - 2019/10

Y1 - 2019/10

N2 - Objective: The aim of this research was to describe and investigate characteristics of patients who underwent surgical removal of the Essure® device (Bayer, Whippany, NJ). This device was the first transcervical micro insert device for permanent sterilization. Materials and Methods: A retrospective chart review was conducted at an academic hospital on patients undergoing surgical removal of the Essure device from 2014 to 2017. Results: A total of 69 patients underwent Essure removal-25 via laparoscopic hysterectomy, 38 via salpingectomy with cornual resection, and 6 via salpingectomy without cornual resection. The mean age of the subjects was 36.4 years (standard deviation [SD] = 7.2). The mean body mass index was 31.7 (SD = 7.3). The most-commonly reported past medical histories were anxiety (19/69) and depression (16/69). Thirty-eight patients had histories of prior surgeries, with cesarean section being reported most commonly (22/38). The most-frequently cited Essure-attributed symptoms were pelvic pain (63/69), bleeding (34/69), and bloating (15/69). When removal was requested, 58/69 patients had had the device in for >1 year and 44/69 patients reported onset of symptoms at time of placement. During the removal surgery, 59/69 patients had additional pelvic intraoperative findings; specifically, 43/69 had endometriosis, 24/69 had adhesions, 22/69 had adenomyosis, 8/69 had fibroids; and 7/69 had misplaced coils. The majority of fallopian tubes were normal/no pathologic alterations (35/69), with smaller subsets of patients having paratubal cysts (26/69) and fibrosis (5/69). Conclusions: Patients seeking removal of the Essure device might have coexisting pelvic pathology. Providers should be prepared to address any intraoperative pathology found.

AB - Objective: The aim of this research was to describe and investigate characteristics of patients who underwent surgical removal of the Essure® device (Bayer, Whippany, NJ). This device was the first transcervical micro insert device for permanent sterilization. Materials and Methods: A retrospective chart review was conducted at an academic hospital on patients undergoing surgical removal of the Essure device from 2014 to 2017. Results: A total of 69 patients underwent Essure removal-25 via laparoscopic hysterectomy, 38 via salpingectomy with cornual resection, and 6 via salpingectomy without cornual resection. The mean age of the subjects was 36.4 years (standard deviation [SD] = 7.2). The mean body mass index was 31.7 (SD = 7.3). The most-commonly reported past medical histories were anxiety (19/69) and depression (16/69). Thirty-eight patients had histories of prior surgeries, with cesarean section being reported most commonly (22/38). The most-frequently cited Essure-attributed symptoms were pelvic pain (63/69), bleeding (34/69), and bloating (15/69). When removal was requested, 58/69 patients had had the device in for >1 year and 44/69 patients reported onset of symptoms at time of placement. During the removal surgery, 59/69 patients had additional pelvic intraoperative findings; specifically, 43/69 had endometriosis, 24/69 had adhesions, 22/69 had adenomyosis, 8/69 had fibroids; and 7/69 had misplaced coils. The majority of fallopian tubes were normal/no pathologic alterations (35/69), with smaller subsets of patients having paratubal cysts (26/69) and fibrosis (5/69). Conclusions: Patients seeking removal of the Essure device might have coexisting pelvic pathology. Providers should be prepared to address any intraoperative pathology found.

UR - http://www.scopus.com/inward/record.url?scp=85073217401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073217401&partnerID=8YFLogxK

U2 - 10.1089/gyn.2018.0111

DO - 10.1089/gyn.2018.0111

M3 - Article

AN - SCOPUS:85073217401

VL - 35

SP - 285

EP - 288

JO - Journal of Gynecologic Surgery

JF - Journal of Gynecologic Surgery

SN - 1042-4067

IS - 5

ER -